AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9103468
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-10 (rhIL-10) 25 microg/kg administered 2 min before endotoxin challenge
Trial: 9103468
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-10 (rhIL-10) 25 microg/kg administered 1 hour after endotoxin challenge
Trial: 9103468
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-10 (rhIL-10) administered both before and after endotoxin challenge
Trial: 28980166
Drug: Intermittent cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cefotaxime dosing regimens
Trial: 28980166
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefotaxime at 100 mg·kg-1·day-1
Trial: 24338947
Drug: Evidence-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based intervention (cognitive-behavioral therapy and/or psychopharmacology)
Trial: 22569436
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg every other day)
Trial: 15675576
Drug: Newer agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer agents (TS‐1, CPT‐11, docetaxel, paclitaxel)
Trial: 7798503
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with streptokinase, recombinant tissue-type plasminogen activator, or anistreplase plus intravenous heparin (5,000 IU bolus followed by 1,000 U/h infusion)
Trial: 6118380
Drug: Dextropropoxyphene preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene preparation (Doleron novum)
Trial: 6118380
Drug: Codeine preparation
RxNorm normalized name: codeine / Erysimum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine preparation (Staralgin)
Trial: 31767717
Drug: 3g oral
RxNorm normalized name: Fosfomycin Tromethamine 3g Oral granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g oral fosfomycin tromethamine every other day (QOD) for 3 doses and then every day (QD) for 7 doses
Trial: 27860267
Drug: RN317 (s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RN317 (s.c. 3.0 mg/kg)
Trial: 27860267
Drug: Bococizumab (s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bococizumab (s.c. 3.0 mg/kg)
Trial: 27860267
Drug: Multiple-dose RN317
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose RN317 (s.c. 300 mg every 28 days; three doses)
Trial: 24967824
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Tranexamic acid (TXA) postoperatively, diluted to 0.2% concentration, gargled or sprayed 5-6 times daily from postoperative day 5-10.
Trial: 24967824
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Tranexamic acid (TXA) postoperatively
Trial: 23110312
Drug: Fibermalt 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibermalt 45 g/d
Trial: 23110312
Drug: Fibermalt 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibermalt 60 g/d
Trial: 23110312
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g/d)
Trial: 21859366
Drug: Iron(III) polymaltose
RxNorm normalized name: Iron (III) oxide adipate
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron(III) polymaltose complex (Maltofer(®)) 100 mg iron twice daily for 90 days
Trial: 21859366
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate 100 mg iron twice daily for 90 days
Trial: 15215110
Drug: BAL5788 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL5788 (750 mg)
Trial: 15215110
Drug: BAL5788 (125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL5788 (125, 250, 500, 750, and 1,000 mg)
Trial: 11521989
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin (400 mg b.i.d.)
Trial: 8168039
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF regimen (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2)
Trial: 8168039
Drug: DES-CMF (CMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES-CMF (CMF preceded by diethylstilbestrol 1 mg orally per day for 3 days)
Trial: 31077751
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D tablet, 1000IU/day (N=180; 69 boys, 111 girls)
Trial: 31077751
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D fortified milk consumption, 200 ml/day, 40IU/100 ml (N=189; 93 boys, 96 girls)
Trial: 28865716
Drug: Risperidone maintenance
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone maintenance treatment for 1 year
Trial: 28865716
Drug: Risperidone treatment
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone treatment length
Trial: 25878120
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of imatinib combined with reduced-intensity chemotherapy (arm A)
Trial: 25878120
Drug: Standard imatinib/hyperCVAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard imatinib/hyperCVAD therapy (arm B)
Trial: 16877377
Drug: Daily 112.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 112.5 IU recombinant FSH from cycle day 2-6 (Group A)
Trial: 16877377
Drug: Daily 112.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 112.5 IU recombinant FSH from cycle day 7-11 (Group B)
Trial: 12508146
Drug: IC14 (anti-CD14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC14 (anti-CD14 antibody)
Trial: 8829932
Drug: Inhalational anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalational anaesthesia with nitrous oxide (induced with thiopentone 6 mg kg‐1, maintained with halothane 1% and nitrous oxide 66% in oxygen)
Trial: 8829932
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia with propofol-alfentanil (induced with alfentanil 25 micrograms kg‐1 and propofol 2 mg kg‐1, maintained with alfentanil and propofol infusions)
Trial: 2056774
Drug: Aclarubicin (ACR)
RxNorm normalized name: aclarubicin
DrugBank: Aclarubicin (DB11617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclarubicin (ACR) 75 mg/m2 daily for 3 days plus cytosine arabinoside (ara‐C) 100 mg/m2 per day for 7 days
Trial: 2056774
Drug: Daunorubicin (DNR)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin (DNR) 45 mg/m2/day for 3 days plus ara‐C for 7 days
Trial: 6601847
Drug: sulfadimidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfadimidine (1 g four times daily for seven days)
Trial: 6601847
Drug: tetracycline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetracycline (500 mg four times daily for seven days)
Trial: 6601847
Drug: trimethoprim‐sulfamethoxazole (TMP‐SMZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim‐sulfamethoxazole (TMP‐SMZ; 160 mg of TMP and 800 mg of SMZ twice daily for seven days)
Trial: 6601847
Drug: doxycycline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline (300 mg as a single dose)
Trial: 6601847
Drug: TMP‐sulfametrole (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP‐sulfametrole (640 mg of TMP and 3,200 mg of sulfametrole once as a single dose)
Trial: 30032464
Drug: Smartphone-based upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based upper airway exercises (15 min of daily gameplay)
Trial: 30032464
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (5 s of daily voice recording)
Trial: 28115223
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via Rotacaps/Rotahaler
Trial: 28115223
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via Diskus
Trial: 28115223
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via either inhaler
Trial: 21121981
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG (LGG) 5.0 × 10⁷ CFU/g, daily intake of 3.4 × 10⁹ CFU for 3 months
Trial: 17451506
Drug: Amine fluoride/stannous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride/stannous fluoride (AmF/SnF(2)) mouthrinse used daily for 3 weeks
Trial: 11386644
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.2 mg/mL applied intraoperatively for 5 minutes)
Trial: 8038981
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol 10 mg (group I)
Trial: 8038981
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml intralipid (group II)
Trial: 2740681
Drug: Single-dose Ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose Ceftriaxone (2 grams)
Trial: 2740681
Drug: Cefamandole (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (multiple doses)
Trial: 1221098
Drug: Drug induced
RxNorm normalized name: Drug induced platelet antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug induced hypotension
Trial: 1221098
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (drug induced hypotension and antifibrinolytic therapy)
Trial: 31521682
Drug: CABG +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CABG + optimal medical therapy
Trial: 25290104
Drug: Cycloidal vibration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloidal vibration therapy applied to the knee extensors twice daily for 7 days
Trial: 25290104
Drug: Stretching and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching and sports massage (SSM) performed twice daily for 7 days
Trial: 23272987
Drug: Mindfulness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness therapy and Enhanced treatment as usual
Trial: 12897045
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation (beta-carotene: 6 mg, vitamin C: 120 mg, vitamin E: 30 mg, zinc: 20 mg, selenium: 100 micro g)
Trial: 10726050
Drug: 75 U
RxNorm normalized name: vitamin E 75 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 U anti‐Xa/kg BW (actual range 63 to 91) once daily started 12 hours before operation
Trial: 10726050
Drug: 50 U
RxNorm normalized name: lipase 650 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 U anti‐Xa/kg BW (actual range 41 to 71) once daily started 2 hours before operation
Trial: 1439060
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (active treatment)
Trial: 1439060
Drug: Acupuncture (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (active treatment)
Trial: 3803821
Drug: Zinc sulfate,
RxNorm normalized name: Zinc sulfate, anhydrous
DrugBank: Zinc sulfate (DB09322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc sulfate, 200 mg daily for 2 months
Trial: 25061313
Drug: Ramipril-based therapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril-based therapy
Trial: 18160685
Drug: Defibrillator implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrillator implantation plus adjunctive catheter ablation
Trial: 12479190
Drug: Remifentanil TCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil TCI at 19 ng x ml(‐1) reduced to 10 ng x ml(‐1) after 1 min
Trial: 12479190
Drug: Remifentanil TCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil TCI at 15 ng x ml(‐1) reduced to 8 ng x ml(‐1) after 1 min
Trial: 12479190
Drug: Remifentanil TCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil TCI at 11 ng x ml(‐1) reduced to 6 ng x ml(‐1) after 1 min
Trial: 12479190
Drug: Propofol TCI
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol TCI at 6.5 microg x ml(‐1) reduced to 3 microg x ml(‐1) after 1 min
Trial: 7926230
Drug: Cefuroxime 1500
RxNorm normalized name: cefuroxime 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1500 mg
Trial: 7926230
Drug: Cefuroxime 750
RxNorm normalized name: cefuroxime 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 750 mg
Trial: 9222726
Drug: Undetectable total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undetectable total IgA (< 0.07 g/l) as a selection criterion for small bowel biopsy
Trial: 3630597
Drug: Intrapleural administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of bupivacaine-adrenaline solution (10 or 20 ml of 2.5 mg/ml or 5 mg/ml)
Trial: 3630597
Drug: Intrapleural administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of bupivacaine-adrenaline solution
Trial: 29020861
Drug: High-dose psilocybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose psilocybin (20 mg/70 kg and 30 mg/70 kg) with standard support (HD-SS)
Trial: 29020861
Drug: High-dose psilocybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose psilocybin (20 mg/70 kg and 30 mg/70 kg) with high support (HD-HS)
Trial: 29020861
Drug: Very low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very low-dose psilocybin (1 mg/70 kg) with standard support (LD-SS)
Trial: 26928904
Drug: Low-equol group
RxNorm normalized name: equol, (+-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-equol group (10 mg/d)
Trial: 26928904
Drug: High-equol group
RxNorm normalized name: equol, (+-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-equol group (20 mg/d)
Trial: 22744655
Drug: Hematoma growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematoma growth (absolute increase of 10.7 mL over 24 hours)
Trial: 22744655
Drug: Hematoma growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematoma growth (1 mL increase)
Trial: 10373769
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid
Trial: 7149895
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three procedures
Trial: 25342290
Drug: Modufolin® (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modufolin® (60 mg/m²)
Trial: 25342290
Drug: Modufolin® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modufolin® (200 mg/m²)
Trial: 25342290
Drug: Isovorin® (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovorin® (60 mg/m²)
Trial: 25342290
Drug: Isovorin® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovorin® (200 mg/m²)
Trial: 22640677
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment (treated group)
Trial: 16463043
Drug: Multi-component physical
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component physical conditioning programme (supervised resistance, aerobic, and balance exercises twice per week, plus home-based exercises once per week)
Trial: 16463043
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily activities (Control group)
Trial: 15243747
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of factors (BL, body mass, active drag factor, passive torque, drag efficiency, hydrostatic lift)
Trial: 31087075
Drug: Zolbetuximab-chemotherapy combination
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab-chemotherapy combination
Trial: 10225539
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 25% metronidazole gel
Trial: 10225539
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (amoxicillin plus clavulanic acid 1 g/day for 14 days)
Trial: 27191794
Drug: Intermediate-acting insulin
RxNorm normalized name: Intermediate-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-acting insulin (IMI)
Trial: 27191794
Drug: Sliding-scale insulin
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding-scale insulin (SSI)
Trial: 17766603
Drug: Acid buffering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid buffering gel plus diaphragm
Trial: 15045133
Drug: Substitution of
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitution of unfractionated heparin by low-molecular-weight heparins for regular anticoagulation
Trial: 11573534
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of thiopental
Trial: 9778007
Drug: Fentanyl and
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl and Propofol combination
Trial: 3198983
Drug: Aminozolamide suspension
RxNorm normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aminozolamide suspension
Trial: 3198983
Drug: Aminozolamide gel
RxNorm normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aminozolamide gel formulation
Trial: 31815582
Drug: FOLFOX (platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin)
Trial: 12809582
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment (NT)
Trial: 10819341
Drug: H. influenzae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. influenzae type b capsular polysaccharide‐tetanus protein conjugate vaccine
Trial: 31473690
Drug: Risk-reduction measures
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-reduction measures (e.g., checking air-quality forecasts, limiting outside activities)
Trial: 24647431
Drug: Pain (induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain (induced by hypertonic saline injection) during bilateral leg squat task
Trial: 20473057
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 25 mg eq.
Trial: 20473057
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 150 mg eq.
Trial: 20473057
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (all doses combined)
Trial: 781661
Drug: Fluocinonide ('Metosyn')
RxNorm normalized name: Fluocinonide
DrugBank: Fluocinonide (DB01047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinonide ('Metosyn') applied once daily
Trial: 781661
Drug: Betamethasone 17-valerate
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 17-valerate ('Betnovate') applied twice daily
Trial: 18824271
Drug: Inhaled human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled human insulin (EXU; Exubera)
Trial: 18824271
Drug: Short-acting subcutaneous
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting subcutaneous (SC) insulin